News

News Subscription

May 05. 2015
Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor
Read more
Download
Apr 29. 2015
Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders
Read more
Download
Apr 24. 2015
Basilea reports isavuconazole and ceftobiprole data to be presented at ECCMID
Read more
Download
Apr 01. 2015
Basilea in-licenses targeted cancer therapy
Read more
Download
Mar 07. 2015
Basilea reports U.S. FDA approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis
Read more
Download
Feb 17. 2015
Basilea reports solid 2014 full-year results, preparing the ground for commercialization of Zevtera® in Europe
Read more
Download
Jan 23. 2015
Basilea announces that FDA's Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis
Read more
Download
Dec 22. 2014
Swissmedic approves Basilea's antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia
Read more
Download
Dec 05. 2014
Basilea announces launch of antibiotic Zevtera® (ceftobiprole medocaril) in Germany
Read more
Download
Nov 21. 2014
Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis
Read more
Download